Polydex Pharmaceuticals Limited
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Polydex Pharmaceuticals Limited develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide, as well as bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. The company primarily offers dextran and derivative products, including iron dextran for treating anemia in pigs; dextran sulphate, a specialty chemical used in biotechnology and pharmaceutical applications; ferric hydroxide; and hydrogenated dextran solutions, supplied through independent distributors, wholesalers, and direct sales to companies. Operations are conducted through wholly-owned subsidiaries Dextran Products in Canada and Chemdex Inc. in the United States, with sales primarily in North America and Europe. Founded in 1979 and headquartered at 421 Comstock Road in Toronto, Ontario, Canada, the company--formerly Polydex Chemicals Limited until its name change in March 1984--focuses on polysaccharide polymers derived from Leuconostoc mesenteroides bacteria, including high and low molecular weight dextran powders and dextran sulfates for industrial and life science applications. In August 2023, Polydex Pharmaceuticals Limited became a subsidiary of BioSpectra Canada, Ltd. and BioSpectra Inc. following the completion of a business combination announced in April 2023 and approved by shareholders in July 2023, enhancing its production capabilities with BioSpectra's cGMP fine chemicals and buffers for biotech and biopharma uses.
Polydex Pharmaceuticals (OTCMKTS:POLXF) Share Price Passes Below 200-Day Moving Average – Here’s What Happened
BioCryst Pharmaceuticals (NASDAQ:BCRX) & Polydex Pharmaceuticals (OTCMKTS:POLXF) Head to Head Analysis
Polydex Pharmaceuticals (OTCMKTS:POLXF) Stock Price Passes Below 200-Day Moving Average – Should You Sell?
Polydex Pharmaceuticals (OTCMKTS:POLXF) Stock Passes Below 200-Day Moving Average – Here’s What Happened
Critical Review: Polydex Pharmaceuticals (OTCMKTS:POLXF) and Nektar Therapeutics (NASDAQ:NKTR)
Polydex Pharmaceuticals (OTCMKTS:POLXF) Stock Crosses Below 200 Day Moving Average – What’s Next?
Polydex Pharmaceuticals (OTCMKTS:POLXF) Stock Passes Below Two Hundred Day Moving Average – Should You Sell?
Polydex Pharmaceuticals Limited and BioSpectra Inc. Announce Business Combination
Polydex Pharmaceuticals Limited Shareholders Vote to Approve BioSpectra Inc. Business Combination